132 results
Page 2 of 7
8-K
fxur83
14 Jun 23
Regulation FD Disclosure
8:53am
8-K
myiz4g9rbo04ez
12 May 23
Regulation FD Disclosure
5:17pm
8-K
EX-99.1
osk7pflr
28 Apr 23
SAB Biotherapeutics Announces Positive Results from Phase 3 Trial of SAB-185 in Patients with COVID-19 at High-Risk for Severe Complications
9:04am
8-K
enxfc4
28 Apr 23
SAB Biotherapeutics Announces Positive Results from Phase 3 Trial of SAB-185 in Patients with COVID-19 at High-Risk for Severe Complications
9:04am
8-K
a87a8d3u40fd
19 Apr 23
SAB Biotherapeutics Announces U.S. FDA Grants Breakthrough Therapy Designation to SAB-176 Influenza Immunotherapy
5:05pm
8-K
EX-99.1
9abm4pu
19 Apr 23
SAB Biotherapeutics Announces U.S. FDA Grants Breakthrough Therapy Designation to SAB-176 Influenza Immunotherapy
5:05pm
8-K
pl2wzvgprwu4klgi9c
14 Apr 23
Regulation FD Disclosure
8:58am
8-K
EX-99.1
6fzokz2
14 Apr 23
Regulation FD Disclosure
8:58am
8-K
EX-99.1
l05lq0nmd8v31c d19
4 Apr 23
SAB Biotherapeutics Announces Appointment of Erick Lucera, CFA to Board of Directors
9:34am
8-K
EX-99.1
xo0aeevoztlo12 hi8l
31 Mar 23
SAB Biotherapeutics Provides Company Update for Full Year 2022
5:12pm
8-K
yv3qlo5br8r1j43l
31 Mar 23
SAB Biotherapeutics Provides Company Update for Full Year 2022
5:12pm
8-K
EX-10.1
gfpyjye9d
12 Dec 22
SAB Biotherapeutics Announces $7.9 Million Private Placement of Common Stock
9:07am